Monraats Pascalle S, Pires Nuno M M, Agema Willem R P, Zwinderman Aeilko H, Schepers Abbey, de Maat Moniek P M, Doevendans Pieter A, de Winter Robbert J, Tio René A, Waltenberger Johannes, Frants Rune R, Quax Paul H A, van Vlijmen Bart J M, Atsma Douwe E, van der Laarse Arnoud, van der Wall Ernst E, Jukema J Wouter
Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.
Circulation. 2005 Oct 18;112(16):2417-25. doi: 10.1161/CIRCULATIONAHA.105.536268.
Restenosis is a negative effect of percutaneous coronary intervention (PCI). No clinical factors are available that allow good risk stratification. However, evidence exists that genetic factors are important in the restenotic process as well as in the process of inflammation, a pivotal factor in restenosis. Association studies have identified genes that may predispose to restenosis, but confirmation by large prospective studies is lacking. Our aim was to identify polymorphisms and haplotypes in genes involved in inflammatory pathways that predispose to restenosis.
The GENetic DEterminants of Restenosis (GENDER) project is a multicenter prospective study, including 3104 consecutive patients after successful PCI. Forty-eight polymorphisms in 34 genes in pathways possibly involved in the inflammatory process were analyzed. The 16Gly variant of the beta2-adrenergic receptor gave an increased risk of target vessel revascularization (TVR). The rare alleles of the CD14 gene (-260T/T), colony-stimulating factor 2 gene (117Thr/Thr), and eotaxin gene (-1328A/A) were associated with decreased risk of TVR. However, through the use of multiple testing corrections with permutation analysis, the probability of finding 4 significant markers by chance was 12%.
Polymorphisms in 4 genes considered involved in the inflammatory reaction showed an association with TVR after PCI. Our results may contribute to the unraveling of the restenotic process. Given the explorative nature of this analysis, our results need to be replicated in other studies.
再狭窄是经皮冠状动脉介入治疗(PCI)的一种不良后果。目前尚无能够进行良好风险分层的临床因素。然而,有证据表明遗传因素在再狭窄过程以及炎症过程(再狭窄的一个关键因素)中都很重要。关联研究已确定了可能易患再狭窄的基因,但缺乏大型前瞻性研究的证实。我们的目的是确定参与炎症途径且易患再狭窄的基因中的多态性和单倍型。
再狭窄的遗传决定因素(GENDER)项目是一项多中心前瞻性研究,纳入了3104例成功接受PCI的连续患者。分析了可能参与炎症过程的途径中34个基因的48个多态性。β2肾上腺素能受体的16Gly变异增加了靶血管再血管化(TVR)的风险。CD14基因(-260T/T)、集落刺激因子2基因(117Thr/Thr)和嗜酸性粒细胞趋化因子基因(-1328A/A)的罕见等位基因与TVR风险降低相关。然而,通过使用置换分析进行多重检验校正,偶然发现4个显著标志物的概率为12%。
4个被认为参与炎症反应的基因中的多态性与PCI术后的TVR相关。我们的结果可能有助于揭示再狭窄过程。鉴于该分析的探索性质,我们的结果需要在其他研究中重复验证。